Wellington Management Group LLP Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Wellington Management Group LLP lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 25.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 129,935 shares of the biotechnology company’s stock after purchasing an additional 26,049 shares during the period. Wellington Management Group LLP’s holdings in Exelixis were worth $3,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of Exelixis by 0.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,048,809 shares of the biotechnology company’s stock valued at $25,161,000 after purchasing an additional 5,833 shares during the last quarter. Bridgefront Capital LLC raised its position in Exelixis by 111.3% in the fourth quarter. Bridgefront Capital LLC now owns 22,847 shares of the biotechnology company’s stock worth $548,000 after acquiring an additional 12,034 shares during the period. True Wealth Design LLC purchased a new position in shares of Exelixis during the 4th quarter worth $828,000. Nomura Holdings Inc. grew its position in shares of Exelixis by 234.4% during the 4th quarter. Nomura Holdings Inc. now owns 194,968 shares of the biotechnology company’s stock valued at $4,677,000 after acquiring an additional 136,668 shares during the period. Finally, Lighthouse Investment Partners LLC bought a new position in Exelixis in the 4th quarter worth $2,971,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Trading Down 0.3 %

Shares of EXEL stock opened at $22.47 on Monday. The stock has a market capitalization of $6.81 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $24.34. The stock’s 50-day moving average price is $21.86 and its 200-day moving average price is $22.33.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). The firm had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business’s revenue was up 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.12 EPS. As a group, research analysts predict that Exelixis, Inc. will post 1.15 EPS for the current fiscal year.

Insider Activity at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 10,923 shares of Exelixis stock in a transaction on Monday, May 13th. The shares were sold at an average price of $21.37, for a total value of $233,424.51. Following the completion of the transaction, the director now directly owns 338,948 shares of the company’s stock, valued at approximately $7,243,318.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total value of $182,314.00. Following the completion of the sale, the director now directly owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 10,923 shares of Exelixis stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $21.37, for a total value of $233,424.51. Following the completion of the transaction, the director now owns 338,948 shares of the company’s stock, valued at approximately $7,243,318.76. The disclosure for this sale can be found here. Insiders have sold a total of 30,896 shares of company stock valued at $660,677 over the last 90 days. 2.85% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EXEL shares. Stephens initiated coverage on Exelixis in a report on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 price target for the company. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a report on Monday, March 18th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Thursday. TD Cowen increased their price objective on shares of Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Finally, JMP Securities restated a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research report on Wednesday, April 10th. Seven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.13.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.